S-adenosyl-L-methionine
[SAMe, S-adenosylmethionine]
Side effects, Health Benefits Research Finds
S-adenosyl-L-methionine [SAMe, S-adenosylmethionine], not abundant in the diet, but is normally
produced in the liver from methionine. Foli acid and vitamin B12 are necessary for the synthesis of
S-adenosyl-L-methionine [S-adenosylmethionine]. Deficiencies of these vitamins always lead to low
concentrations of
S-adenosyl-L-methionine [S-adenosylmethionine] in the central nervous system
[1]. Low blood or central nervous system levels of
S-adenosyl-L-methionine [S-adenosylmethionine]
is also associated with cirrhosis of the liver, coronary heart disease, Alzheimer's disease and
depression [2-4].

S-adenosyl-L-methionine [S-adenosylmethionine] participates in over 40 essential biochemical
reactions including detoxifications and in the manufacture of brain chemicals, antioxidants, joint
tissue structures [5,6]. It is found that
S-adenosyl-L-methionine [S-adenosylmethionine] may raise
levels of dopamine [7,8]. Consequently, it has been demonstrated to be an effective treatment for
depression in some studies [9-15, 16, 17].
S-adenosyl-L-methionine [S-adenosylmethionine] is also
found to be anti-inflammatory, pain-relieving, and tissue-healing that may support the health of
joints [18-27, 28].

Researchers finds that
S-adenosyl-L-methionine [S-adenosylmethionine] may be helpful in various
liver conditions such as cholestasis, Gilbert's syndrome, alcoholic liver injury, and cirrhosis [29-31].
S-adenosyl-L-methionine [S-adenosylmethionine] may also increase sperm activity in infertile men
[32].

Recent Research Studies

Anti-Cancer

Pascale RM et al, University of Sassari, Italy, observed a decrease in S-adenosyl-L-methionine
[SAMe, S-adenosylmethionine]
content in the liver, associated with DNA hypomethylation in rat liver,
during the development of preneoplastic foci, and in neoplastic nodules and hepatocellular
carcinomas, induced in diethylnitrosamine-initiated rats by "resistant hepatocyte" (RH) protocol.
Reconstitution of the methyl donor level in the liver by
S-adenosyl-L-methionine [SAMe,
S-adenosylmethionine]
administration inhibits growth and induces phenotypic reversion and
apoptosis of preneoplastic cells. They proposed a few possible mechanisms for its chemopreventive
effect
[Alcohol. 2002 Jul;27(3):193-8].

Simile MM et al, Universita di Sassari, Italy, stated that S-adenosyl-L-methionine
[S-adenosylmethionine]
is a strong chemopreventive agent of rat liver carcinogenesis. They found
S-adenosyl-L-methionine [S-adenosylmethionine] causes a persistent decrease in growth capacity
of preneoplastic liver lesions in rats subjected to a diethylnitrosamine/TB protocol in their studies.

[Carcinogenesis. 1996 Jul;17(7):1533-7].

Alcoholic Liver Damage

Stickel F et al, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Germany, stated that
S-adenosyl-L-methionine [S-adenosylmethionine], pentoxifylline, metadoxin,
polyenylphosphatidylcholine or inhibitors of the cytochrome P450 2E1 isoenzyme are promising to
treat alcoholic liver damage in their review article.
[Z Gastroenterol. 2003 Apr;41(4):333-42].

Alzheimer's Disease

Cohen BM et al, McLean Hospital, Belmont, MA, did not found S-adenosyl-L-methionine
[S-adenosylmethionine]
, produced neither improvement nor worsening of symptoms in patients with
Alzheimer's disease (AD)
[J Clin Psychopharmacol. 1988 Feb;8(1):43-7].

Though Eto K et al, National Center of Neurology and Psychiatry, Japan, observed that
S-adenosyl-L-methionine [S-adenosylmethionine], a CBS activator, is much reduced in AD brain
[Biochem Biophys Res Commun. 2002 May 24;293(5):1485-8].

Depression

Pancheri P et suggested that S-adenosyl-L-methionine [S-adenosylmethionine] may be useful in
treatment of depression
[Int J Neuropsychopharmacol. 2002 Dec;5(4):287-94].

Alpert JE et al, Harvard Medical School, concluded that augmentation of selective serotonin
reuptake inhibitors or venlafaxine with
S-adenosyl-L-methionine [S-adenosylmethionine] warrants a
placebo-controlled trial in resistant depression
[J Clin Psychopharmacol. 2004 Dec;24(6):661-4].

Toxicity / SIDE EFFECT

Goren JL et al, McLean Hospital, Massachusetts, concluded that oral dosages of 1600 mg/day of
S-adenosyl-L-methionine [S-adenosylmethionine] appear to be significantly bioavailable and
nontoxic
[Pharmacotherapy. 2004 Nov;24(11):1501-7].

S-adenosyl-L-methionine [ S-adenosylmethionine] may cause Parkinson's disease-like syndromes
[33].

This Article is for your reference only. If you have any questions, please, consult with your doctor.



References

1. Bottiglieri T, Hyland K, Reynolds EH. Drugs 1994;48:137-52 [review].2. Osman E, Owen JS, Burroughs AK. Aliment Pharmacol Ther
1993;7:21-8 [review].3. Loehrer FM, Angst CP, Haefeli WE, et al. Arterioscler Thromb Vasc Biol 1996;16:727-33. 4. Bottiglieri T,
Godfrey P, Flynn T, et al. J Neurol Neurosurg Psychiatry 1990;53:1096-8. 5. Chiang PK, Gordon RK, Tal J, et al. FASEB J
1996;10:471-80 [review]. 6. Bottiglieri T, Hyland K, Reynolds EH. Drugs 1994;48:137-52 [review]. 7. Fava M, Rosenbaum JF,
MacLaughlin R, et al. J Psychiatr Res 1990;24:177-84. 8. Bell KM, Potkin SG, Carreon D, Plon L. Acta Neurol Scand
1994;154(suppl):15-8. 9. Bell KM, Potkin SG, Carreon D, Plon L. Acta Neurol Scand 1994;154(suppl):15-8. 10. Bressa GM. Acta
Neurol Scand 1994;154(suppl):7-14. 11. Salmaggi P, Bressa GM, Nicchia G, et al. Psychother Psychosom 1993;59:34-40. 12. Kagan
BL, Sultzer DL, Rosenlicht N, et al. Am J Psychiatry 1990;147:591-5. 13. Fava M, Rosenbaum JF, Birnbaum R, et al. Acta Psychiatr
Scand 1992;86:42-5. 14. De Vanna M, Rigamonti R. Curr Ther Res 1992;52:478-85. 15. Fava M, Giannelli A, Rapisarda V. Psychiatr
Res 1995;56:295-7. 16. Tavoni A, Jeracitano G, Cirigliano G. Clin Exp Rheumatol 1998;16:106-7 [letter]. 17. Tavoni A, Vitali C,
Bombardieri S, et al. Am J Med 1987;83(suppl 5A):107-10. 18. Schumacher HR. Am J Med 1987;83(suppl 5A):1-4 [review]. 19.
Harmand MF, Vilamitjana J, Maloche E, et al. Am J Med 1987;83(suppl 5A):48-54. 20. Domljan Z, Vrhovac B, Durrigl T, Pucar I. Int J
Clin Pharmacol Ther Toxicol 1989;27:329-33. 21. Muller-Fassbender H. Am J Med 1987;83(suppl 5A):81-3. 22. Vetter G. Am J Med
1987;83(suppl 5A):78-80. 23. Maccagno A. Am J Med 1987;83(suppl 5A):72-7. 24. Caruso I, Pietrogrande V. Am J Med 1987;83(suppl
5A):66-71. 25. Marcolongo R, Giordano N, Colombo B, et al. Curr Ther Res 1985;37:82-94. 26. Glorioso S, Todesco S, Mazzi A, et al.
Int J Clin Pharmacol Res 1985;5:39-49. 27. Montrone F, Fumagalli M, Sarzi Puttini P, et al. Clin Rheumatol 1985;4:484-5. 28.
Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Scand J Rheumatol 1991;20:294-302. 29. Angelico M, Gandin C, Nistri A, et al.
Scand J Clin Lab Invest 1994;54:459-64. 30. Frezza M, Surrenti C, Manzillo G, et al. Gastroenterology 1990;99:211-5. 31.
Bombardieri G, Milani A, Bernardi L, Rossi L. Curr Ther Res 1985;37:580-5. 32. Mato JM, Cámara J, Fernández J, et al. J Hepatol
1999;30:1081-9.
Does SAMe [S-adenosylmethionine] have health benefits on depression?
All rights reserved.